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Abstract
PB1-F2 is a 90 amino acid protein that is expressed from the +1o p e nr e a d i n gf r a m ei nt h eP B 1g e n eo fs o m ei n f l u e n z a
A viruses and has been shown to contribute to viral pathogenicity. Notably, a serine at position 66 (66S) in PB1-F2 is
known to increase virulence compared to an isogenic virus with an asparagine (66N) at this position. Recently, we
found that an influenza virus expressing PB1-F2 N66S suppresses interferon (IFN)-stimulated genes in mice. To
characterize this phenomenon, we employed several in vitro assays. Overexpression of the A/Puerto Rico/8/1934 (PR8)
PB1-F2 protein in 293T cells decreased RIG-I mediated activation of an IFN-b reporter and secretion of IFN as
determined by bioassay. Of note, the PB1-F2 N66S protein showed enhanced IFN antagonism activity compared to
PB1-F2 wildtype. Similar observations were found in the context of viral infection with a PR8 PB1-F2 N66S virus. To
understand the relationship between NS1, a previously described influenza virus protein involved in suppression of IFN
synthesis, and PB1-F2, we investigated the induction of IFN when NS1 and PB1-F2 were co-expressed in an in vitro
transfection system. In this assay we found that PB1-F2 N66S further reduced IFN induction in the presence of NS1. By
inducing the IFN-b reporter at different levels in the signaling cascade, we found that PB1-F2 inhibited IFN production
at the level of the mitochondrial antiviral signaling protein (MAVS). Furthermore, immunofluorescence studies revealed
that PB1-F2 co-localizes with MAVS. In summary, we have characterized the anti-interferon function of PB1-F2 and we
suggest that this activity contributes to the enhanced pathogenicity seen with PB1-F2 N66S- expressing influenza
viruses.
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Introduction
Influenza viruses cause annual epidemics and occasional
pandemics which may result in up to 50 million excess deaths as
seen during the outbreak in 1918 [1]. The virus strains causing the
influenza pandemics that occurred in the years of 1918, 1957 and
1968, all have been found to express the virulence factor PB1-F2.
The PB1-F2 protein is encoded by the +1 alternate open reading
frame (ORF) in the PB1 gene of some influenza A viruses, giving
rise to a 90 amino acid protein that was initially found to possess
pro-apoptotic activity [2]. In animal studies, PB1-F2 has been
shown to contribute to pathogenesis by delaying viral clearance,
potentially by eliminating immune cells via apoptosis [3]. A recent
study has identified a single point mutation at amino acid position
66 in the PB1-F2 protein of the 1918 pandemic and of an H5N1
influenza virus strain, which is associated with increased virulence
[4]. This mutation consists of a change of the amino acid
asparagine (66N) to serine (66S) and causes increased weight loss
and viral loads in infected mice. In search of the molecular
mechanism for these findings, microarray analyses on whole lung
homogenates of mice infected with isogenic viruses expressing
either PB1-F2 66N or 66S were performed. Interestingly, infection
with a virus expressing PB1-F2 N66S lead to a suppression of
interferon-stimulated genes (ISGs) at an early stage of infection [5].
In the present study, we aim to verify these findings in vitro and
elucidate the molecular mechanism for the IFN antagonism
function of PB1-F2 N66S.
The innate immune system is the first line of defense in response
to viral infection. Besides Toll-like receptors (TLR) and Nod-like
receptors (NLRs) in the endosome and cytoplasm, respectively,
RNA helicases such as the retinoic acid inducible gene-I (RIG-I)
and the melanoma differentiation-associated gene-5 (MDA-5) are
able to recognize characteristic patterns of invading pathogens and
induce the production of type I interferons (IFN), potent antiviral
molecules [6,7]. In influenza virus infected cells, RIG-I has been
shown to be the major sensor of viral RNA leading to type I IFN
production, as knock down of RIG-I expression has been de-
monstrated to abolish type I IFN secretion in response to virus
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regulated by the so-called enhanceosome, constituted by the
transcription factors IRF3/7, NF-kB and ATF/c-Jun [9]. Upon
recognition of viral RNA species, RIG-I interacts with the
mitochondrial antiviral signaling protein (MAVS, also known as
IPS-1, VISA, CARDIF) in the mitochondrial membrane. This
leads to the phosphorylation and activation of both IRF3 and
IRF7 by IKKe and TBK1 [10]. Upon secretion, IFN binds to
specific IFN receptors in an autocrine or paracrine manner and
activates the JAK/STAT pathway. This leads to the formation of
the ISG factor 3 (ISGF3) transcription complex which drives the
expression of antiviral genes such as protein kinase R (PKR), Mx
GTPases and others.
Viruses have evolved mechanisms to counteract the antiviral
IFN production and/or signaling pathways. Nipah virus V protein
has been shown to bind STAT1 and thus inhibit nuclear
translocation of ISGF3 [11,12]. The VP35 protein of Ebola virus
can block IFN induction by interacting with both TBK1 and
IKKe and interfere with the phosphorylation of IRF3 [13].
Influenza virus expresses the non-structural protein 1 (NS1) which
can inhibit IFN induction using multiple strategies [14]. NS1 has
been shown to bind dsRNA and thus mask viral RNA species from
recognition [15,16]. Furthermore, NS1 interacts with RIG-I and
its co-activator TRIM25 leading to impaired activation of the
IRF3, ATF/c-Jun and NF-kB transcription factors that drive IFN-
b expression [17,18,19,20]. In addition, NS1 can interact with
PKR and inhibit its activation [21,22]. Recent reports describe an
IFN antagonism function also for PB2 and other polymerase
proteins [23,24]. In the study by Graef et al. [23], PB2 was found
to interact with MAVS at the mitochondria and thus impair IFN-b
production without apparently affecting viral replication in vitro.
Besides NS1, PB1-F2 is another non-structural protein of
influenza viruses [25]. In contrast to NS1, the molecular
mechanism for the contribution of PB1-F2 to the pathogenicity
of influenza virus has not been thoroughly studied. PB1-F2 triggers
the intrinsic apoptosis pathway by interacting with the mitochon-
drial adenine nucleotide translocator 3 (ANT3) and voltage-
dependent anion channel 1 (VDAC1) proteins in vitro [26] and it
induces apoptosis in a strain-specific way [27]. Several studies
demonstrated that PB1-F2 has pro-inflammatory activity and
exerts its function as a virulence factor by causing increased
immune cell infiltration, elevated cytokine levels and tissue
damage [4,27,28]. A study by Mazur et al. describes an interaction
of PB1-F2 with the PB1 subunit of the viral polymerase complex in
virus infected cells, but this interaction does not seem to contribute
to pathogenicity in a mouse model [29,30].
In search for residues in the PB1-F2 protein that confer
increased virulence, we have previously identified a serine at
position 66 that is associated with increased pathogenicity by
suppressing the early IFN response in a mouse infection model
[4,5]. Herein, we confirm and characterize the IFN antagonism
function of PB1-F2 in vitro, finding that a serine at position 66
enhances the anti-IFN activity in an overexpression system, when
expressed from a Newcastle disease virus (NDV) vector as well as
in the context of influenza virus infection. Furthermore, we show
that PB1-F2-mediated IFN suppression is exerted via its C-
terminal domain at the level of the MAVS adaptor protein. We
also investigated the relationship between PB1-F2 and the well
characterized IFN antagonist NS1 and observed that PB1-F2
N66S in combination with NS1 lead to lower IFN induction
compared to NS1 alone.
Based on our results we propose that PB1-F2 proteins of highly
pathogenic influenza virus strains contribute to pathogenesis by
suppressing the host innate response at the level of the MAVS
adaptor protein. This is the first report that links a molecular
mechanism to the observed pathogenic phenotype caused by PB1-
F2 in vivo.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Labo-
ratory Animals of the National Institutes of Health. The protocol
was approved by the Institutional Animal Care and Use Co-
mmittee at Mount Sinai School of Medicine (Permit Number: 03-
0058). Mice were sacrificed for the isolation of bone marrow
according to these guidelines and all efforts were made to
minimize suffering.
Cell lines and antibodies
Madin Darby Canine Kidney (MDCK), 293T, Vero and A549
cells were obtained from ATCC (Manassas, VA, USA) and were
maintained in Minimal Essential Medium (MEM) or Dulbecco’s
Modified Eagle Medium (DMEM) (Gibco, Invitrogen, San Diego,
CA, USA) supplemented with 10% fetal bovine serum (FBS,
Hyclone, South Logan, UT, USA) and penicillin/streptomycin
(Gibco). LA-4 cells were obtained from ATCC and maintained in
F-12K medium (Gibco) supplemented with 15% FBS (Hyclone)
and penicillin/streptomycin (Gibco). The generation of the
MDCK cell line constitutively expressing the IFN-b reporter
(MDCK-IFN-beta luc) has been described before [31] and this cell
line was maintained in DMEM with 10% FBS (Hyclone) and
penicillin as well as hygromycin and geneticin (Gibco). Monoclo-
nal antibodies to actin, FLAG and HA were obtained from Sigma-
Aldrich (St.Louis, MO, USA). NP protein levels were detected
using a monoclonal NP antibody generated by our laboratory
(clone 28D8). The polyclonal rabbit NS1 antibody was raised
against amino acids 1–73 of the Tx/98 swine virus NS1 protein.
The polyclonal rabbit sera against PB1-F2 has been described
before [26]. The polyclonal rabbit serum against NDV was
prepared by Dr. Qinshan Gao.
Author Summary
Influenza viruses can cause global pandemics and are thus
a major health concern. The novel H1N1 pandemic virus
infected a large number of people, but resulted in
relatively mild symptoms in the majority of cases. In
contrast, the avian H5N1 viruses are associated with a high
mortality rate, but are not transmitted from human to
human. Understanding the viral and host factors that play
a role in causing disease is crucial in developing effective
vaccines and therapeutics. Furthermore, finding viral
markers for high virulence may help predict the impact
of newly emerging pandemic influenza viruses. We have
previously established that a single amino acid substitu-
tion (N66S) in the viral PB1-F2 protein causes increased
virulence in an H5N1 and the 1918 pandemic virus. Here
we show that PB1-F2 N66S reduces the induction of
interferon (IFN), a potent antiviral molecule secreted by
cells in response to infection. Furthermore, we demon-
strate that the inhibition of IFN by PB1-F2 N66S occurs at
the level of the mitochondrial antiviral signaling protein
(MAVS), a key player in the IFN production pathway. Our
work here characterizes a new function for the PB1-F2
protein and how this function can lead to increased
disease severity.
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dendritic cells (DCs)
Peripheral blood mononuclear cells were isolated by Ficoll
density gradient centrifugation (Histopaque, Sigma- Aldrich)
from buffy coats of healthy human donors (New York Blood
Center) as previously described [32]. Briefly, CD14-positive cells
were immunomagnetically purified using anti-human CD14
antibody-labeled magnetic beads and iron-based MiniMACS
LS columns (Miltenyi Biotec, Auburn, CA, USA). After elution
from the columns, cells were plated (10
6 cells/mL) in DC
medium (RPMI medium [Invitrogen], 2 mM L-glutamine
[Invitrogen], 1 mM Sodium Pyruvate [Invitrogen] and penicil-
lin-streptomycin [Invitrogen] and 10% FBS [Hyclone]) supple-
mented with 500 U/mL human granulocyte macrophage colony-
stimulating factor (GM-CSF, Peprotech, Rocky Hill, NJ, USA),
and 1,000 U/mL human interleukin-4 (IL-4, Peprotech) and
incubated for 5 days at 37uC.
Murine dendritic cells were obtained from bone marrow as
described previously [33]. Bone marrow was prepared from the leg
bones of 7–9 week old BL/6 mice (Jackson Laboratories, Bar
Harbor, ME, USA). Tibia and femur were aseptically dissected
and the bone marrow flushed out. Bone marrow cells were
cultured with Iscove’s modified Dulbecco’s medium (Gibco)
supplemented with GM-CSF (20 ng/mL; Peptrotech), non-
essential amino acids (Gibco), 50 mM b-mercaptoethanol (Gibco),
10% FBS (Hyclone) and penicillin-streptomycin (Gibco) at 37uCi n
5% CO2 for 7 days. Fresh media was added every second day.
Floating dendritic cells were recovered and seeded for subsequent
viral infection the following day.
Rescue of recombinant influenza and Newcastle disease
viruses
The influenza A/Puerto Rico/8/1934 (PR8; H1N1) viruses
were rescued as described previously [34]. Briefly, 293T cells were
transfected with seven bidirectional pDZ constructs for PB2, PA,
NP, HA, NA, M and NS (giving rise to viral genomic and
messenger RNAs) as well as a pPolI construct expressing the
wildtype (WT) or the PB1-F2 N66S PB1. In addition, four
pCAGGS protein expression vectors encoding the subunits of the
WSN viral polymerase and the nucleocapsid protein were added.
The transfected 293T cells were injected into 10-day old
embryonated chicken eggs (Charles Rivers Laboratories, Wil-
mington, MA, USA) and propagated for 48 h. Rescued viruses
were plaque purified on MDCK cells, propagated in 10-day old
embryonated chicken eggs and sequenced to confirm the presence
of the introduced mutations. The N66S mutation in the PB1-F2
open reading frame was introduced by a single point mutation at
position 315 in the PB1 gene which changed the nucleotide from
an A to a G using the Stratagene Quick-Change mutagenesis kit
(Stratagene, La Jolla, CA, USA). This mutation does not affect the
PB1 amino acid sequence. For rescue of the recombinant PR8
virus expressing a dsRNA/TRIM25 binding mutant form of NS1
(R38A/K41A), a pCAGGS-NS1 expression plasmid has been
added to the 293T transfection mixture and 7-day old embryo-
nated chicken eggs (Charles Rivers Laboratories) were used as
described before [20].
The PB1-F2 (WT and N66S, PR8) expressing Newcastle disease
viruses (NDV) were generated from the LaSota strain cDNA as
described before [35,36]. The PB1-F2 and GFP genes were
inserted into the NDV genome between the P and M segments via
Sac II restriction sites. The NDV-GFP virus was prepared by Dr.
Qinshan Gao [37] . The NDV-NS1 (B1 strain) virus has been
described previously [32].
Infection of cells with NDV or influenza viruses
Primary human DCs were infected with the NDV recombinant
viruses at a multiplicity of infection (MOI) of 2 or the NS1
dsRNA/TRIM25 binding mutant PR8 influenza viruses at an
MOI of 0.5 in serum-free DC media for 45 min at 37uC. After the
adsorption time, DCs were plated in complete DC medium and
incubated for indicated timepoints at 37uC. Then, cells were
recovered by centrifugation at 4006g for 10 min for subsequent
RNA isolation. In addition, supernatants were collected for
cytokine production evaluation by Multiplex ELISA (Millipore,
Billerica, MA, USA). Adherent cells were washed with PBS and
virus diluted in PBS supplemented with 0.3% bovine albumin (BA,
Gibco) and penicillin streptomycin (Gibco) was added for 1 h at
37uC. Cells were subsequently washed and growth media was
added in case of single cycle analyses. For multicycle analyses,
DMEM (Gibco) supplemented with 0.1% FBS (Hyclone) and
0.3% BA (Gibco) including 1 mg/mL trypsin was added.
RNA isolation
RNA from human DCs (5610
5) was extracted using the Abso-
lutely RNA Microprep Kit (Stratagene). RNA yields were evaluated
in a Nanodrop spectrophotometer (Nanodrop technologies, Wil-
mington, DE, USA) at 260 nm, and 500 ng of RNA was reverse
transcribed using the iScript cDNA Synthesis Kit (Bio-Rad,
Hercules, CA, USA) according to the manufacturer’s instructions.
RNA from all other cells was harvested using b-mercaptoethanol-
containing RLT buffer from the RNeasy Qiagen kit and RNA was
extracted following the manufacturer’s instructions; cDNA was
generated using the Superscript First-Strand RT-PCR kit (Invitro-
gen) according to the manufacturer’s instructions.
Quantitative real- time PCR (qRT-PCR)
Evaluation of mRNA levels was carried out using iQ SYBR
Green SuPermix (Bio-Rad) according to the manufacturer’s
instructions. The PCR temperature profile was 95uC for 10 min,
followed by 40 cycles of 95uC for 10 s, 60uC for 60 s. The mRNA
levels of target genes were normalized to a-tubulin and rps11
expression for human DCs and 18S for all other cell types,
respectively. The sequences of the primers used for qRT-PCR
analyses on DC samples have been described elsewhere [38]. The
primers for viral M and PB1 RNA levels detect cRNA, vRNA and
mRNA and the sequences are as follows: 59-TCAGGCCCCCT-
CAAAGCCGA-39 (forward) and 59-GGGCACGGTGAGCGT-
GAACA-39 (reverse) for M, 59-AATTCTTCCCCAGCAGT-
TCA-39 (forward) and 59-TTTTTGCCGTCTGAGCTCTT-39
(reverse) for PB1. The primers used to quantify murine IFN-b are
59-CAGCTCCAAGAAAGGACGAAC-39 (forward) and 59-GG-
CAGTGTAACTCTTCTGCAT-39 (reverse). The primers for
murine IP-10 are: 59-TTCACCATGTGCCATGCC-39 (forward)
and 59-GAACTGACGAGCCTGAGCTAGG-39 (reverse). The
primers used for A549 cells are: 59-TCTGGCACAACAGGTAG-
TAGGC-39 (forward) and 59-GAGAAGCACAACAGGAGAG-
CAA-39 (reverse) for IFN-b,5 9-GTAACCCGTTGAACCCCAT-
T-39 (forward) and 59-CCATCCAATCGGTAGTAGCG-39 (re-
verse) for 18S and 59-GGAACCTCCAGTCTCAGCACCA-39
(forward) and 59-AGACATCTCTTCTCACCCTTC-39 (reverse)
for IP-10. All experiments included biological triplicates and tech-
nical duplicates. CXF Manager software (Bio-Rad) was used to
analyze the normalized relative mRNA levels in the samples.
Cytokine quantification in human DC supernatants
The levels of IFN-a and IP-10 proteins in human DC
supernatants after infection was quantified using the MILLIPLEX
PB1-F2 Inhibits Interferon by Affecting MAVS
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pore) according to the manufacturer’s instructions. Data were
analyzed using the Milliplex Analyst Software (Millipore).
Expression plasmids and cloning
The pCAGGS vector possessing a chicken b-actin promoter has
been described previously [39]. An N-terminal FLAG tag was
added to PB1-F2 WT and N66S (PR8) as well as NS1 genes (PR8)
by PCR with 59 gene-specific primers containing the tag sequence
and cloned into pCAGGS using EcoRI and XhoI restriction sites.
The HA-tagged Nipah virus V protein, the FLAG-tagged Ebola
virus VP35 protein, FLAG-tagged RIG-I N, HA-tagged MAVS,
FLAG-tagged TRIF, FLAG-tagged TBK1 and IKKe, IRF3-5D
expression plasmids have been described elsewhere [13,40]. The
generation and subcellular localization of the PB1-F2 truncation
constructs have been described previously [26].
Growth curves of recombinant viruses
Ten-day old embryonated chicken eggs (Charles Rivers Labo-
ratories) were inoculated with 100 plaque forming units (PFU)
of virus and incubated at 37uC for the indicated amount of time
and subsequently placed at 4uC. Allantoic fluids were harvested
and centrifuged at 3,000 rpm for 30 min at 4uC. A549 cells
were infected at a multiplicity of infection (MOI) of 0.01 and
supernatants were harvested at the indicated time points and
centrifuged at 1,200 rpm for 5 min to remove cell debris. The
viral titers were determined via plaque assays on MDCK cells.
NDV-GFP bioassay
The NDV-GFP bioassay to quantify IFN levels has been
described before [12]. Briefly, 293T cell supernatants were
harvested and spun down at 1,200 rpm for 5 min to remove cell
debris. Vero cells grown in a 96-well format were overlaid with
serial 2-fold dilutions of the supernatants for 24 h and subse-
quently infected with NDV-GFP at an MOI of 5. The fluorescence
intensities were measured with a plate reader (Beckman Coulter
DTX 880 instrument) at 18–24 hours post infection (hpi)
(excitation wavelength: 485 nm, emission wavelength: 535 nm).
Images were taken using a fluorescence microscope (Olympus
IX70).
Reporter assays
For IFN-b reporter assays, 293T cells were transfected with
lipofectamine 2000 (Invitrogen) at a ratio of 1:1 with plasmid DNA
and lysed 24 h post transfection. For the ISRE reporter assay,
transfected 293T cells were stimulated with 1000 U/mL of
universal type I interferon (PBL interferon source, Piscataway,
NJ, USA) and lysed 24 h later. For luciferase assays, cells were
lysed using the provided lysis buffer by the dual-luciferase assay kit
according to the manufacturer’s instructions (Promega, Madison,
WI, USA). The fold-induction was calculated as the ratio of
stimulated versus unstimulated samples. Expression plasmids for
RIG-I N, MAVS, TBK1, IKKe, IRF3-5D and TRIF were
transfected as stimuli for the IFN-b reporter assays.
Western blot analysis
Cells were lysed in urea buffer (6 M urea, 2 M b-mercaptoeth-
anol, 4% sodium dodecyl sulfate [SDS]) and sonicated three times
at output level 3.0 for 5 s. Samples were run on 4–20% precast
gradient gels (Bio-Rad) and transferred onto polyvinylidene
fluoride (PVDF) membranes (GE Healthcare, Buckinghamshire,
UK). Blotting against HA or FLAG-tagged proteins as well as
PB1-F2, actin and viral proteins was achieved by using antibody
dilutions of 1:1000 in 5% non-fat dry milk-containing PBS-Tween-
20 0.05%. Anti-NP, NS1 and NDV antibodies were used at a
dilution of 1:2000 and 1:5000, respectively. Horseradish peroxi-
dase-conjugated secondary antibodies (GE Healthcare) were used
at a dilution of 1:5000.
Confocal microscopy studies
Hela cells were transfected as described above for 293T cells to
overexpress HA-tagged MAVS, FLAG-tagged PB1-F2 or empty
vector and allowed to adhere to round glass slides in a 24-well
plate. Twenty-four h post transfection, cells were fixed with 4%
para-formaldehyde and stained with anti-FLAG and anti-HA
antibodies as well as DAPI. Secondary antibodies conjugated to
Alexa 488 and Alexa 555 (Invitrogen) were used to visualize the
proteins. Images were taken on an LSM 510 Meta confocal
microscope (Carl Zeiss MicroImaging GmbH, Jena, Germany) at
a magnification of 1006. Confocal laser scanning microscopy was
performed at the MSSM-Microscopy Shared Resource Facility,
supported with funding from NIH-NCI shared resources grant
(5R24 CA095823-04), NSF Major Research Instrumentation
grant (DBI-9724504) and NIH shared instrumentation grant (1
S10 RR0 9145-01).
Results
PB1-F2 overexpression impairs RIG-I N induced type I IFN
production
In our previous study we have shown that an influenza virus
expressing PB1-F2 66S of an H5N1 virus suppresses interferon-
stimulated genes (ISGs) at an early stage of infection in vivo
compared to an isogenic virus expressing PB1-F2 66N [5]. To
confirm and characterize the interferon (IFN) antagonism function
of PB1-F2, we employed several in vitro assays. We first examined
whether PB1-F2 could block IFN secretion induced by constitu-
tively active RIG-I, since RIG-I is the most upstream molecule
involved in triggering the antiviral IFN response against influenza
virus. We transfected 293T cells, which are highly transfectable,
with a plasmid expressing constitutively active RIG-I (RIG-I N) as
well as an empty vector (pCAGGS), NS1 (PR8) or PB1-F2 (PR8)
WT or N66S expressing constructs and measured IFN secretion
by these cells in an NDV-GFP bioassay. Vero cells were overlaid
with 293T cells supernatants and infected with NDV-GFP virus
24 hours later. The replication efficiency of the NDV-GFP virus is
a measure for the amount of IFN in the supernatants where a high
GFP signal indicates IFN suppression activity and low GFP
expression is a read-out for high IFN concentrations. Expression of
an empty vector did not block RIG-I N induced IFN secretion,
whereas the well described IFN antagonist NS1 enabled NDV-
GFP to replicate efficiently (Figure 1A). Interestingly, overexpres-
sion of PB1-F2 also blocked IFN production and a serine at
position 66 (N66S) showed an increased IFN antagonism activity
in the NDV-GFP bioassay (Figure 1A). We did not observe any
cytopathic effects by expressing PB1-F2 proteins without any
additional stimuli which is in accordance with previous findings
[26].
Of note, the NDV-GFP bioassay measures not only the amount
of secreted IFN, but also the activity of other antiviral molecules.
Hence, to examine whether PB1-F2 interferes with the activation
of the IFN-b promoter, we performed an IFN-b reporter assay,
using a reporter construct that carries the IFN-b promoter driving
the expression of a firefly luciferase gene. This reporter was
transfected into 293T cells along with a constitutively expressed
renilla luciferase reporter control to monitor cytotoxicity and
transfection efficiency. As shown in Figure 1B, overexpression of
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which was not affected by the empty vector control (pCAGGS),
but was efficiently blocked by NS1. In accordance with the
bioassay data, PB1-F2 decreased activation of the IFN-b reporter
and PB1-F2 N66S was approximately two-fold more efficient in
inhibiting the reporter compared to PB1-F2 wildtype (WT) at
equal protein amounts (Figure 1B). Compared to NS1, PB1-F2
WT inhibited IFN induction about four times less efficiently,
whereas PB1-F2 N66S was only two-fold less efficient than NS1 in
these assays (Figure 1A and 1B). We also tested the influenza virus
nucleoprotein (NP) and observed no inhibition of the RIG-I N
induced IFN-b reporter (data not shown). To examine whether
PB1-F2 proteins from other strains besides PR8 could inhibit IFN
induction, we tested both PB1-F2 66N and 66S proteins from the
A/Brevig Mission/1/1918 (H1N1) pandemic and A/Viet Nam/
1203/2004 (H5N1) strains and found similar results (data not
shown). Activation of RIG-I leads to the secretion of type I IFN
which binds to IFN receptors to activate the JAK/STAT pathway
resulting in the establishment of an antiviral state in a paracrine or
autocrine manner. To examine whether PB1-F2 is also able to
interfere with IFN signaling, we employed an interferon-
stimulated response element (ISRE) reporter assay that contains
an ISG54 promoter fused to a firefly luciferase gene. 293T cells
were transfected with ISRE and renilla reporters as well as an
empty vector, PB1-F2 plasmids or a vector expressing Nipah virus
V protein as a positive control [11]. Twenty-four hours post
transfection, 293T cells were treated with universal type I IFN and
analyzed for reporter activity 24 hours later. Nipah virus V
protein strongly repressed activation of the ISRE reporter,
whereas empty and PB1-F2 expressing vectors did not affect the
ISRE reporter (Figure 1C). We have also not observed an effect of
PB1-F2 on the ISRE reporter in unstimulated cells (data not
shown).
The C-terminal domain of PB1-F2 mediates its IFN
antagonism activity
It has been demonstrated that a C-terminal portion of PB1-F2
interacts with both ANT3 and VDAC1 to induce apoptosis, while
an N-terminal fragment of PB1-F2 is not able to trigger cell
death [26]. In view of this finding, we tested whether the IFN
antagonism function of PB1-F2 was confined to the N- or C-
terminal domain. For this purpose, we used an N-terminal
fragment of PB1-F2 which contains amino acids 1–38 and a C-
terminal portion that contains amino acids 39–87 of the PR8 PB1-
F2 protein. The design of the PB1-F2 truncations is based on
previous structural data by Bruns et al. [41]. Of note, the C-
terminal domain includes the mitochondrial localization sequence
(MLS). These PB1-F2 fragments were fused to GFP for protein
stability and also contain an N-terminal HA tag as described
previously [26]. As shown in Figure 1D, the C-terminal fragment
and the full-length PB1-F2 protein which is also fused to GFP and
contains an HA tag, inhibited the IFN-b reporter to similar levels.
Conversely, the N-terminal portion was unable to block the
reporter even though it was expressed at higher levels than the
other constructs. It is possible that localization of these peptides to
the mitochondria is necessary for the IFN antagonism function, so
we also tested an N-terminal PB1-F2 fragment that contains an
MLS derived from the human cytochrome C oxidase as described
by Zamarin et al. [26]. Even though this peptide localizes to the
mitochondria as efficiently as the full-length PB1-F2 construct
[26], it was still unable to suppress IFN induction in this assay
(data not shown). Collectively, these results suggest that the C-
terminus, which contains the characteristic amphihelical structure,
mediates the IFN antagonism function of PB1-F2.
PB1-F2 N66S decreases IFN activation in the context of
viral infection
To investigate whether PB1-F2 66S is a stronger IFN antagonist
than PB1-F2 66N in the context of influenza virus infection, we
employed reverse genetics to generate a PR8 influenza virus
expressing PB1-F2 66S or 66N (WT). We then examined the
growth kinetics of these two viruses in A549 cells, a human lung
epithelial cell line which supports efficient viral replication, and in
10-day old embryonated chicken eggs. Both viruses displayed
similar replication kinetics in both A549 cells and in ovo (Figure 2A).
We next examined IFN induction by these two viruses at early
timepoints of infection. For this purpose we infected an MDCK
IFN-b reporter cell line with the PR8 viruses either expressing
PB1-F2 66N or 66S. At 4 hours post infection (hpi), PR8 WT virus
induced the IFN-b reporter approximately 5-fold over mock
infected cells. This weak induction is due to the strong IFN
antagonist activity of the NS1 protein. Yet, PR8 N66S suppressed
the IFN-b reporter by 2-fold compared to the PR8 WT virus
(Figure 2B). At 8 and 12 hpi similar results were observed. Of
note, this phenomenon was not due to increased PB1-F2 protein
expression by the PR8 N66S virus (data not shown). NS1 and NP
proteins from both viruses were expressed at equal levels with
increasing protein expression over time, as determined by Western
blot analysis, indicating that the enhanced IFN suppression activity
by the PR8 N66S virus was not due to increased replication in
these cells or higher NS1 protein expression (Figure 2B). In
Western blots with higher exposure, NP protein levels are visible at
4 hpi showing similar levels in PR8 WT and PR8 N66S virus
infected cells (Figure 2B).
The IFN antagonism function of PB1-F2 N66S is not cell-
type specific
It has been suggested that PB1-F2 exerts its pro-apoptotic
function specifically in immune cells [2]. We thus examined the
IFN antagonism function of PB1-F2 N66S in both epithelial as
Figure 1. PB1-F2 inhibits RIG-I N induced IFN via its C-terminal domain. (A) IFN secretion was determined via NDV-GFP bioassay. 293T cells
were transfected with empty vector (pCAGGS), NS1 or PB1-F2 WT or N66S expressing vectors as well as a RIG-I N expression plasmid. Twenty-four
hours post transfection, supernatants were harvested and serial two-fold dilutions of the supernatants were used to overlay Vero cells. Twenty-four
hours later, Vero cells were infected with NDV-GFP and images were taken 18 hpi. To quantify the GFP signals, the plate was analyzed by a plate
reader with an excitation wavelength of 485 nm and an emission wavelength of 535 nm. (B) 293T cells were transfected as described in (A) with the
addition of IFN-b and renilla reporter constructs. Twenty-hour hours post transfection, cells were harvested and luciferase and renilla signals were
determined by luminometry. In addition, cells were harvested for Western blot analyses. (C) 293T cells were transfected as described in (A) with the
addition of ISRE and renilla reporter constructs. Twenty-hour hours post transfection, cells were treated with 1,000 U/mL of universal type I IFN.
Twenty-four hours after IFN treatment, cells were harvested for luminometry and Western blot analyses. (D) 293T cells were transfected and analyzed
as described in (B). Besides full-length PB1-F2, following truncation constructs were tested for IFN antagonism activity: the N-terminal domain
consisting of amino acids 1–37 (nF2) and the C-terminal domain spanning amino acids 38–87 (cF2). All constructs carried an HA tag and were fused to
GFP. All data represent means 6 standard deviations of one representative experiment (n=3). Statistical significance was determined using Student’s
t test. *, p,0.05; **, p,0.01; ***, p,0.001. All data shown are representatives of at least three independent experiments.
doi:10.1371/journal.ppat.1002067.g001
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PR8 viruses expressing either 66N or 66S PB1-F2 at an MOI of 2
and RNA was harvested 8 hpi to analyze gene expression via
qRT-PCR. Infection with PR8 WT virus induced IFN-b mRNA
levels approximately 20-fold over mock (Figure 2C). Infection with
PR8 N66S, in contrast, induced two-fold less IFN-b (Figure 2C).
We also examined mRNA levels of IP-10, an ISG, which showed a
similar trend to the IFN-b induction by the two PR8 viruses
(Figure 2C).
We also infected murine lung epithelial (LA-4) cells with the
PR8 viruses and quantified IFN-b as well as IP-10 mRNA levels.
Infection with PR8 WT virus did not efficiently increase IFN-b in
these cells over mock treated cells, but we observed a two-fold
suppression of IFN-b induction by the PR8 N66S virus
(Figure 2D). In LA-4 cells, there was a more pronounced
suppression of IP-10 mRNA levels compared to dendritic cells
(Figure 2C and 2D).
PB1-F2 N66S expressed from an NDV vector suppresses
the induction of IFN in human dendritic cells
Newcastle disease virus (NDV) has been shown to be a potent
IFN inducer by activating RIG-I [42]. Therefore, we asked the
question whether PB1-F2 could block NDV induced IFN
activation in primary human dendritic cells. Dendritic cells are
important immune effector cells that are involved in clearing viral
infections by secreting pro-inflammatory cytokines as well as type I
IFN and bridging the innate and adaptive immune responses. It
has been demonstrated that primary human dendritic cells are a
suitable ex vivo model to study human influenza A virus host
responses [43]. We generated recombinant NDV viruses that
express GFP or PB1-F2 (WT and N66S) and infected primary
human dendritic cells to investigate the induction of type I IFN in
this model. As shown in Figure 3A, NDV-PB1-F2 N66S replicated
more efficiently than the NDV-PB1-F2 WT and NDV-GFP
viruses at 18 hpi and 22 hpi. To test whether this growth
advantage may be due to suppressed IFN induction by PB1-F2
N66S expressed from the NDV vector, we analyzed IFN induction
at 14 hpi by the three recombinant NDV viruses when replication
was still found to be similar. NDV-GFP induced high levels of IFN
as well as IP-10 as measured by qRT-PCR and ELISA (Figure 3B
and 3C). Expression of PB1-F2 WT did not suppress IFN and IP-
10 levels compared to GFP, whereas PB1-F2 N66S efficiently
inhibited IFN induction in NDV infected dendritic cells (Figure 3B
and 3C). These results indicate that PB1-F2 N66S is also able to
suppress IFN production in primary human dendritic cells
confirming that this inhibitory effect is not strictly cell type-specific.
PB1-F2 N66S decreases IFN induction in the presence of
an NS1 mutant deficient in dsRNA/TRIM25 binding
The NS1 protein is the major IFN antagonist of influenza
viruses as the knockout of NS1 strongly attenuates the virus in
IFN competent cells [44]. NS1 employs multiple strategies to
counteract the initiation and establishment of an antiviral state in
virus infected cells [45]. One of these strategies is the masking of
viral RNA species from recognition by RIG-I [16,17]. Within the
N-terminal domain of NS1, the basic residues R38 and K41 were
found to mediate binding to dsRNA species [16] and mutating
these residues to alanine was shown to induce a robust IFN
response in influenza virus infected cells [15]. In addition, these
mutations also result in loss of NS1 interaction with TRIM25, an
interaction that is required for inhibition of RIG-I activation
mediated by this E3 ligase [20]. We thus aimed to examine the
IFN induction by viruses that express a dsRNA/TRIM25 binding
mutant form of NS1 and PB1-F2 66N or 66S. For this purpose we
rescued PR8 viruses with the described point mutations in NS1
(R38A/K41A) and those that express the WT or N66S form of
PB1-F2. Infection of the MDCK-IFN-b reporter cell line with
these two mutant viruses resulted in approximately 3 log higher
induction of the IFN-b reporter compared to the PR8 viruses with
WT NS1 at 8 hpi (Figure 2B and 4A). At 4 hpi, no remarkable
difference in IFN induction was seen between the PB1-F2 66N or
66S expressing viruses. At 8 hpi, however, the NS1 dsRNA/
TRIM25 binding mutant virus expressing PB1-F2 66S induced
significantly less IFN than the isogenic virus expressing PB1-F2
66N (Figure 4A). At 12 hpi, the difference in IFN induction
became minimal (Figure 4A) and a substantial detachment of cells
was observed at this time point (data not shown). At 4 hpi and
8 hpi, the NP and NS1 protein levels were comparable in cells
infected with both viruses. Of note, the NP protein levels in cells
infected with the NS1 mutant viruses do not increase as
dramatically between 4 and 8 hpi compared to those in cells
infected with PR8 viruses expressing wildtype NS1 (Figure 2B).
This finding indicates that the NS1 dsRNA binding mutant viruses
are attenuated compared to the wildtype NS1 expressing viruses.
Next, we infected primary human dendritic cells with the NS1
dsRNA/TRIM25 binding mutant viruses and analyzed the
induction of type I IFN via qRT-PCR and ELISA. At 6 hpi and
8 hpi, IFN-b mRNA as well as IFN-a protein levels were
decreased by the PB1-F2 N66S expressing virus compared to
the isogenic virus (Figure 4B and 4C) which confirms the data
obtained in the MDCK IFN-b reporter cell line (Figure 4A). We
also performed qRT-PCR analyses to quantify IFN-a mRNA
levels and found a similar trend to IFN-b mRNA levels (data not
shown). To test this phenomenon in epithelial cells, we also
infected A549 cells with the dsRNA/TRIM25 binding mutant
NS1 viruses. As shown in Figure 4D, the PB1-F2 N66S expressing
virus induced less IFN and IP-10 compared to the PB1-F2 WT
virus at 6 hpi and 8 hpi (data not shown). In summary, these data
demonstrate that even in the presence of an NS1 protein that lacks
the dsRNA and TRIM25 binding function, PB1-F2 66S is able to
reduce the induction of IFN compared to PB1-F2 66N.
PB1-F2 N66S enhances NS1 mediated IFN antagonism
To characterize the relationship between NS1 and PB1-F2
regarding IFN antagonism, we overexpressed NS1 with either
Figure 2. PB1-F2 N66S induces less IFN compared to PB1-F2 WT in the context of viral infection. (A) Growth curves of PR8 WT and PR8
N66S viruses in A549 cells and in ovo. A549 cells were infected with virus at an MOI of 0.01 and aliquots of the supernatants were taken at 4, 24, 48
and 72 hpi. To determine viral titers, supernatants were plaqued on MDCK cells. Ten-day old embryonated chicken eggs were inoculated with
100 PFU of virus and placed at 4uC at 12, 24, 48 and 72 hpi. The following days, allantoic fluids were harvested, spun down and titered via plaque
assays on MDCK cells. (B) An MDCK cell line expressing an IFN-b promoter driven luciferase reporter (MDCK-IFN-beta luc) was infected with PR8 WT
and PR8 N66S viruses at an MOI of 2. Cells were lysed at 4, 8 and 12 hpi and luciferase activity was measured. In addition, cell lysates were analyzed
for protein expression via Western blots. (C and D) Primary murine dendritic cells (C) or murine lung epithelial cells (D) were infected with the
indicated PR8 viruses at an MOI of 2. RNA was isolated 8 hpi and subjected to qRT-PCR. All data represent means 6 standard deviations of one
representative experiment (n=3). Statistical significance was determined using Student’s t test. *, p,0.05; **, p,0.01. Statistical significance is
relative to PR8 WT. All data shown are representatives of at least two independent experiments.
doi:10.1371/journal.ppat.1002067.g002
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the IFN-b reporter activated by RIG-I N. As shown in Figure 5A,
PB1-F2 66N did not significantly reduce IFN promoter activation
compared to the empty vector control when co-expressed with NS1.
In contrast, PB1-F2 66S further decreased IFN induction when co-
expressed with NS1 even though PB1-F2 66N is expressed more
efficiently as shown in Western blot analyses (Figure 5A). To
confirm these findings in the human DC model, we performed
a co-infection experiment with the recombinant NDV viruses.
Co-infection of human DCs with NDV-NS1 and NDV-PB1-F2
66N induced similar levels of IFN compared to co-infection with
NDV-NS1 and NDV-GFP (Figure 5B). In contrast, co-infection of
primary human DCs with NDV-NS1 and NDV-PB1-F2 N66S
strongly reduced type I IFN and IP-10 mRNA levels (Figure 5B).
Collectively, these data indicate that PB1-F2 N66S, but not
PB1-F2 WT, enhances the IFN antagonism activity of NS1.
PB1-F2 inhibits the induction of IFN at the level of MAVS
In order to examine at which stage the PB1-F2 protein inhi-
bits the IFN production pathway, we used different stimuli
Figure 3. PB1-F2 N66S inhibits NDV induced IFN in primary human dendritic cells. (A) Primary human dendritic cells were infected with
NDV-GFP, NDV-PB1-F2 WT or NDV-PB1-F2 N66S at an MOI of 2 and NDV HN was determined via qRT-PCR at 6,14,18 and 22 hpi. (B and C) At 14 hpi,
qRT-PCR analyses were performed for IFN-alpha and IP-10 mRNA levels. In addition, supernatants were collected for ELISA analyses to quantify IFN-a
and IP-10 protein secretion. All data represent means 6 standard deviations of one representative experiment (n=3). Statistical significance was
determined using Student’s t test. *, p,0.05; **, p,0.01; ***, p,0.001. Statistical significance is relative to NDV-GFP. The data presented in B and C
are representatives of five independent experiments with different donors.
doi:10.1371/journal.ppat.1002067.g003
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expressing an IFN-b promoter driven luciferase reporter (MDCK-IFN-beta luc) was infected with PR8 viruses expressing the dsRNA/TRIM25 binding
mutant form of NS1 (R38A/K41A) as well as PB1-F2 WT or PB1-F2 N66S at an MOI of 0.5. Cells were lysed at 4, 8 and 12 hpi and luciferase activity was
measured. In addition, cell lysates were analyzed for protein expression via Western blot analyses. (B and C) Primary human dendritic cells were
infected with the viruses described in (A) at an MOI of 0.5 and RNA was harvested for qRT-PCR analyses at 6 and 8 hpi (B). In addition, supernatants
were analyzed for IFN-alpha secretion via ELISA (C). (D) A549 cells were infected with the viruses described in (A) at an MOI of 0.5 and RNA was
analyzed via qRT-PCR at 6 hpi. All data represent means 6 standard deviations of one representative experiment (n=3). Statistical significance was
determined using Student’s t test. *, p,0.05; **, p,0.01. Statistical significance is relative to PB1-F2 WT. Data shown are representatives of two
independent experiments.
doi:10.1371/journal.ppat.1002067.g004
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We overexpressed MAVS, TBK1, IKKe and IRF3-5D, a phos-
phomimetic form of IRF3, and analyzed the activation of the IFN-
b reporter in the presence of PB1-F2. We observed that PB1-F2
WT and N66S inhibited the MAVS-induced IFN-b reporter, but
did not affect any factors downstream of MAVS such as TBK1
or IRF3-5D (Figure 6A, 6C, 6D). We performed densitometry
analyses and found that the MAVS expression levels were not
decreased in NS1, PB1-F2 WT or PB1-F2 N66S expressing cells
compared to the empty vector control (data not shown). Upon
stimulation with IKKe, we found a slight enhancement of the IFN-
b reporter activity in cells expressing PB1-F2 WT (Figure 6B). For
TBK1 and IKKe (Figure 6B and 6C), Ebola virus VP35 protein
was used as a positive control since it has been previously
Figure 5. PB1-F2 N66S further enhances NS1 mediated IFN antagonism in an overexpression system. (A) 293T cells were transfected
with IFN-b reporter, renilla reporter, RIG-I N expression plasmid and the indicated combination of expression plasmids. Twenty-four hours post
transfection, luciferase and renilla signals were determined by luminometry. In addition, Western blot analyses were applied to determine protein
expression levels from cell extracts. (B) Primary human dendritic cells were co-infected with the indicated combination of recombinant NDV viruses at
an MOI of 1 per virus. RNA was harvested and subjected to qRT-PCR 14 hpi. All data represent means 6 standard deviations of one representative
experiment (n=3). Statistical significance was determined using Student’s t test. *, p,0.05; **, p,0.01; ***, p,0.001. Statistical significance is relative
to NS1+pCAGGS and NDV-NS1+NDV-GFP. Data presented in A are representatives of two independent experiments and data in B are representatives
of three independent experiments performed in different donors.
doi:10.1371/journal.ppat.1002067.g005
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with the phosphorylation of IRF3 [13]. NS1 has been reported to
inhibit MAVS in an IFN-b reporter assay by a yet unclear
mechanism [46]. To confirm that PB1-F2 inhibits IFN production
at the level of MAVS, we tested whether PB1-F2 affects a TRIF-
induced IFN-b reporter. TRIF is an adaptor protein that mediates
IFN production upon activation of endosomal TLRs in a MAVS-
independent manner. As shown in Figure 6E, the PB1-F2 proteins
did not affect TRIF-induced IFN which indicates that PB1-F2
inhibits IFN in a MAVS-dependent fashion.
Next, we investigated whether PB1-F2 co-localizes with MAVS
at the mitochondria to confirm the reporter assay data shown in
Figure 6A. For this purpose we overexpressed HA-tagged MAVS
and FLAG-tagged PB1-F2 proteins in Hela cells and examined
localization patterns via confocal microscopy. We chose Hela
cells for our studies because they have been previously used to
investigate MAVS localization upon influenza virus infection [47].
As shown in Figure 7A, both PB1-F2 66N and 66S co-localized
with MAVS while the influenza virus nucleoprotein (NP), which
does not affect IFN induction (data not shown), did not. It has
been reported that MAVS undergoes a redistribution in the
mitochondrial membrane upon activation of the IFN pathway
[47]. We thus asked whether PB1-F2 could also associate with
redistributed MAVS. Upon infection of transfected Hela cells with
Sendai virus (SeV), we observed a relocalization of MAVS into
distinct speckle-like structures (Figure 7B) as has been shown
previously by Onoguchi et al. [47]. Interestingly, PB1-F2 also co-
localized with these structures, while NP did not appear to do so
(Figure 7B). In summary, these data indicate that PB1-F2 inhibits
the induction of IFN at the level of MAVS, possibly by interacting
with MAVS and/or affecting MAVS function.
Discussion
In our previous work, we have shown that infection of mice with
a recombinant influenza virus expressing PB1-F2 of the H5N1
Hong Kong 1997 strain with an N66S mutation results in
decreased IFN induction in the lungs compared to infection with
the isogenic wildtype virus without affecting the levels of the
induction of apoptosis [5]. Here, we report on the molecular
mechanism by which an N66S point mutation in the PR8 PB1-F2
protein leads to decreased IFN induction in both overexpression as
well as viral infection models (Figure 1 and 2). We show that PB1-
F2 wildtype (66N) has IFN antagonism activity in a RIG-I N
induced IFN-b reporter assay and an NDV-GFP bioassay when
overexpressed in 293T cells. However, the anti-interferon function
of PB1-F2 66N seems to be weaker than that of NS1 or PB1-F2
66S in a 293T cell overexpression system (Figure 1A and 1B). In
human dendritic cells, PB1-F2 66N shows no to minimal IFN
antagonism activity compared to GFP when expressed from an
NDV vector that induces high levels of IFN. This may be due to a
diminished IFN antagonism activity of the PB1-F2 WT protein in
immune cells (Figure 3). These results indicate that PB1-F2 66N is
a weaker IFN antagonist than NS1 or PB1-F2 66S in all systems
studied. Interestingly, PR8 N66S virus suppressed IP-10 mRNA
levels to a greater extent in epithelial cells than in dendritic cells
(Figure 2C and 2D) which may have to do with a differential
regulation of IP-10 expression in these cell types.
We also tested the PB1-F2 proteins of the 1918 pandemic and
the A/Viet Nam/1203/2004 (H5N1) viruses and found an
inhibition of RIG-I N induced IFN-b reporter in 293T cells (data
not shown). We thus believe that the IFN antagonism activity of
PB1-F2 is a general function shared by various influenza A virus
strains. The pro-apoptotic activity was found to be mediated by
the C-terminal domain of PB1-F2 which interacts with VDAC1
and ANT3 [26]. Interestingly, we also found that this C-terminal
region spanning amino acids 38 to 87 was sufficient to inhibit
the induction of IFN (Figure 1D). Further work will focus on
characterizing the minimal region needed to suppress IFN and
identifying key residues mediating the IFN antagonism function of
PB1-F2. Also, it will be important to determine the relationship
between the pro-apoptotic and anti-interferon function of PB1-F2.
A recent report describes a possible anti-apoptotic role of MAVS
by interacting with and destabilizing VDAC1 [48]. PB1-F2 might
interfere with the interaction between MAVS and VDAC1 and
thus decrease IFN production while promoting VDAC1-mediated
cell death. Further work will be necessary to test this hypothesis.
Of note, a recent report by Le Goffic et al. indicates that PB1-F2
enhances the induction of IFN in epithelial cells [49]. In
agreement with the findings of Le Goffic et al., we observed
decreased IFN levels of a PR8 virus lacking PB1-F2 compared to
wildtype PR8 virus. Further characterization of the PB1-F2
knockout virus revealed increased levels of the N40 protein in
infected cells, while N40 protein levels expressed by the PB1-F2
N66S virus were similar to that found in wildtype virus infected
cells (data not shown). The increased N40 expression levels in
PB1-F2 (PR8) knockout virus infected cells is in accordance with a
report by Wise et al. [50]. N40 is a third protein expressed from the
PB1 gene and has been identified as a truncated form of PB1 [50].
It is possible that the reduced IFN levels caused by PB1-F2
knockout viruses are due to altered N40 expression levels and we
thus feel that the use of a PB1-F2 knockout virus is not suitable to
assess the induction of IFN.
Despite the reduced induction of IFN by PB1-F2 N66S, we do
not observe a growth advantage of the PR8 PB1-F2 N66S virus in
A549 cells or embryonated chicken eggs (Figure 2A). It is possible
that moderate differences in IFN levels induced by the virus do not
affect viral replication in a cell line that is highly adapted to
support influenza virus growth. PB1-F2 N66S may confer a
growth advantage in cells where NS1 may be non-functional or
restricted in its IFN antagonism capability. In fact, we have shown
that a virus containing mutations that render NS1 deficient in
dsRNA and TRIM25 binding induces high levels of IFN and
PB1-F2 66S is able to reduce the induction of IFN by this virus
compared to PB1-F2 66N (Figure 4). Furthermore, overexpression
of PB1-F2 N66S in combination with NS1 further enhances the
anti-IFN activity of NS1 (Figure 5). PB1-F2 N66S may target a
protein that is not affected by NS1 or support NS1 in inhibiting a
particular factor important for IFN production.
We found that PB1-F2 inhibits a MAVS-induced IFN-b
reporter, but doesn’t affect the reporter when induced by factors
that are downstream in the IFN production pathway, namely the
Figure 6. PB1-F2 inhibits IFN induction at the level of MAVS. (A–E). 293T cells were transfected with an IFN-b reporter, a renilla reporter and
one of the following to induce the IFN-b reporter: MAVS-HA (A), IKKe-FLAG (B), TBK1-FLAG (C), IRF3-5D (D) or TRIF-FLAG (E) expression plasmids. Also,
pCAGGS, expression plasmids for PB1-F2 WT or N66S or a positive control (NS1 or VP35) were transfected. Twenty-four hours post transfection,
lysates were harvested for luminometry and Western blot analyses. The unit on the y-axis indicates fold induction over Mock. All data represent
means 6 standard deviations of one representative experiment (n=3). Statistical significance was determined using Student’s t test. *, p,0.05;
**, p,0.01; ***, p,0.001. All data shown are representatives of at least two independent experiments.
doi:10.1371/journal.ppat.1002067.g006
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pCAGGS expressing FLAG-NP, FLAG-PB1-F2 WT or N66S. Twenty-four hours post transfection, cells were fixed with 4% para-formaldehyde (A) or
infected with Sendai virus for 18 hours and subsequently fixed (B). Fixed cells were stained with anti-FLAG and anti-HA antibodies as well as DAPI.
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necessary to identify the domain of MAVS and/or adaptor
proteins targeted by PB1-F2.
The question arises how a mutation from an asparagine to
serine at position 66 could increase the IFN antagonism function
of PB1-F2. This residue lies within the minimal mitochondrial
targeting sequence of PB1-F2 [51] and it is possible that an N66S
mutation alters the efficiency of mitochondrial targeting, poten-
tially by altering the secondary structure. This may allow for more
efficient interactions with MAVS and/or insertion into the
mitochondrial membrane to disrupt MAVS function, for example
by interfering with the interactions of MAVS with adaptor
proteins. Alternatively, an N66S mutation could create a
phosphorylation site that is now recognized by cellular kinases.
Multiple IFN antagonists of influenza virus have been described
(NS1, PB1, PB2, PA, PB1-F2) [5,23,24,44] which demonstrates
that the IFN antagonism strategies used by influenza virus are
more complex than previously thought. It will be important to
study and understand the biological significance for this functional
redundancy. In this report, we have characterized the IFN
antagonism function of PB1-F2 and provide evidence that PB1-F2
N66S works in conjunction with NS1. Further work will be needed
to understand the interplay between PB1-F2 and the polymerase
proteins regarding IFN antagonism. Overall, our findings
contribute to understanding the molecular mechanism for PB1-
F2 mediated pathogenicity and highlight the importance of
position 66 in the PB1-F2 protein for virulence.
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